A comparative study on the influence of the cost of capital on the development of national biotechnology industries within developing countries
by D. Walwyn
International Journal of Biotechnology (IJBT), Vol. 6, No. 1, 2004

Abstract: For a number of reasons, developing countries lag significantly behind OECD nations in their ability to benefit from the recent advances in biotechnology. One of the reasons for this difference is the virtual absence and hence high cost of loan or equity capital. In this paper, the extent to which the ''cost of capital'' presents an impediment to the commercialisation of biotechnology innovation within emerging economies is quantified. A number of recommendations for both senior policy makers within government, and emerging companies within developing countries are made in order to inform a revised strategy for overcoming this hurdle.

Online publication date: Wed, 26-May-2004

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com